

Application No. 08/211,312

- 40. A purified polypeptide having the amino acid sequence of at least one of the polypeptides selected from the group consisting of UreE, UreF, UreG, UreH, and UreI, as shown in Figure 4 (SEQ. ID NOS: 4-7 and 3, respectively), or a fragment thereof.
- 41. The purified polypeptide of claim 40, wherein said polypeptide is UreE.
- 42. The purified polypeptide of claim 40, wherein said polypeptide is UreF.
- 43. The purified polypeptide of claim 40, wherein said polypeptide is UreG.
- 44. The purified polypeptide of claim 40, wherein said polypeptide is UreH.
- 45. The purified polypeptide of claim 40, wherein said polypeptide is UreI.
- 46. A purified polypeptide having an amino acid sequence expressed by a gene selected from the group consisting of ureE, ureF, ureG, ureH, and ureI (SEQ ID NO:1) of H. pylori, or a mutant thereof.
- 47. The purified polypeptide of claim 46, wherein said gene is ureE (SEQ ID NO:1) or a mutant thereof.
- 48. The purified polypeptide of claim 46, wherein said gene is ureF (SEQ ID NO:1) or a mutant thereof.
- 49. The purified polypeptide of claim 46, wherein said gene is ureG (SEQ ID NO:1) or a mutant thereof.
- 50. The purified polypeptide of claim 46, wherein said gene is ureH (SEQ ID NO:1) or a mutant thereof.
- 51. The purified polypeptide of claim 46, wherein said gene is ureI (SEQ ID NO:1) or a mutant thereof.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L. L. P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

Application No. 08/211,312

52. A purified polypeptide having the following amino acid sequence:

Ala Lys Ile Cys Tyr Glu Ile Gly Asn Arg His.

53. A purified antibody, which binds to the polypeptide according to any one of claims 40-45.

54. A purified antibody, which binds to the polypeptide according to any one of claims 46-51.

55. A purified antibody, which binds to the polypeptide according to claim 52.

56. A composition comprising the antibody of claim 53 and a pharmaceutically acceptable carrier.

57. A composition comprising the antibody of claim 54 and a pharmaceutically acceptable carrier.

58. A composition comprising the antibody of claim 55 and a pharmaceutically acceptable carrier.

59. A composition comprising the polypeptide of any one of claims 40-45 and a pharmaceutically acceptable carrier.

60. A composition comprising the polypeptide of any one of claims 46-51 and a pharmaceutically acceptable carrier.

61. A composition comprising the polypeptide of claim 52 and a pharmaceutically acceptable carrier...

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L. L. P.
1300 1 STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

REMARKS